BioCentury
ARTICLE | Clinical News

QLT091001: Phase Ib data

May 9, 2011 7:00 AM UTC

Interim data from 12 patients in an open-label, Canadian Phase Ib trial showed that QLT091001 resulted in clinically meaningful improvement in visual field and/or visual acuity in 8 patients. Visual field was significantly improved by 22-217% from baseline to day 14 in 7 evaluable patients. In 9 patients evaluable for visual acuity, 2 had improvements of 3-6 lines for 6 and 14 months, respectively, and a third showed a 2-line improvement. ...